AlfredHealth (A.P.A.)

Alfred Pathology Service

MOLECULAR HAEMATOLOGY TEST REQUEST FORM



PATIENT INFORMATION		REQUESTIN	G CLINICIAN / PATHOLOGIST
Surname:	Sex: M / F	Name:	
First Name:	DOB:	Hospital/Lab:	
Address:		Provider No:	
		Tel:	Fax:
Medicare Number:		Referrer Signature:	
Private Health Fund: Health Fund	nd Number:	Date:	
	CLINICAL AND SAMP		a deepting fair responsibility for this pathology request.
Clinical Notes / Reason for Test:	(Attach a copy of relevant F	athology Reports)	Sample Details Collection Date/Time: Bone Marrow Blood Other (specify) Container Type (circle) EDTA / DNA / RNA / Trizol
SELECT TEST(S)			
 FIP1L1::PDGFRA <u>Myeloid NGS Panel</u> - 52 genes - Suspected Myeloid Malignand PMF, Transplant eligible (MBS ET/PV (MBS item 73398) SELECT PAYMENT OPTION Bill Medicare (Patient must sign. Non-reb If a test is being requested through Medicare the pati Private Patient in a private hospital or approv Private Patient in a recognised hospital Public Patient in a recognised hospital Outpatient in a recognised hospital 	PM1 K2 V617F list of targets on page 2 cy (MBS item 73447) S item 73399) Detable components will be bin ient's hospital status at the time of ved day hospital Patient's Signature:	*Please provide d when sending the first sample to the IDH1 IDH1 IDH2 KMT2 FLT3-	Specify Mutation Type*
Medicare Assignment Form (Section 20A of the I assign my right to benefits to the approved patholog		e requested pathology	service(s).
Bill Hospital/Pathology Provider Direct	t		
Bill Patient Direct (Must sign declaration	on overleaf) 🛛 Other: _		
 PROVIDE THE FOLLOWING: This completed form Appropriate sample (Please see page Copy of the Pathology Test Report if r Your doctor recommended that you use Alfred Pathology. You However, if your doctor has specified a particular pathologist of You should discuss this with your doctor. Privacy Note: The information provided will be used to asses 	are free to choose your own pathology on clinical grounds, a Medicare rebate v	Alfred Hospital, Fax: (03) 90 provider. vill only be payable if that	
health programs, and may be used to update enrolment recon Department of Health and Ageing or to a person in the medica	ds. Its collection is authorised by provis	sion of the Health Insuran	ce Act 1973. The information may be disclosed to the

Test	Genes/targets covered	Price*
Myeloid NGS panel (52 genes)	ASXL1, BCOR, BCORL1, CALR (exon 9), CBL (exon 2-3, 6-10, 13, 15), CEBPA, CISH, CSF3R (exon 14, 17), DDX41, DNMT3A, EPOR, ETV6, EZH2, FLT3 (exon 14-17, 20, 21), FOXO3, GATA2, GNAS, IDH1 (exon 4, 7-9), IDH2 (exon 4, 7), JAK1 (exon 14), JAK2 (exon 1-14, 16-	
All exons in the genes	25), JAK3, KIT (exon 8, 11, 13-14, 17-18), KLF3, KRAS (exon 2-4), MPL, NF1, NFE2, NPM1 (exon 12), NRAS (exon 2-3), PHF6, PTPN11 (exon 3, 8, 11-13), PPM1D, RAD21, RUNX1,	MBS73399 \$601.30
listed are covered unless otherwise specified	SETBP1 (partial exon 4), SF3B1 (12, 14-15), SH2B3, SMC1A, SMC3, SOCS1, SOCS2, SOCS3, SRSF2 (exon 1, 2), STAG1, STAG2, STAT5B, TET2, TP53, U2AF1 (exon 2, 6) WT1 (exon 6-8), ZRSR2.	MBS73398 \$357.00
NPM1 MRD	RT-qPCR - c.860_863dup (Type A), RT-ddPCR - c.863_864insNNNN	\$196.35
IDH1/2 HRM	IDH1 R132, IDH2 R140 and R172	
IDH1 ddPCR	c.394C>T p.R132C, c.394C>G p.R132G c.394C>A p.R132S c.395G>A p.R132H, c.395G>T p.R132L	\$196.35
IDH2 ddPCR	c.419G>A p.R140Q, c.515G>A p.R172K	\$196.35
KMT2A::X RT-ddPCR	t(9;11)(p23;q23)/KMT2A::MLLT3, t(6;11)(q27;q23)/KMT2A::AFDN, t(10;11)(p12;q23)/KMT2A::MLLT10 t(11;19)(q23;p13.1)/KMT2A::ELL, t(11;19)(q23;p13.3)/KMT2A::MLLT1, t(4;11)(q21;q23)/KMT2A::AFF1	\$196.35
JAK2 ddPCR	c.1849G>T p.V617F	\$63.35
FLT3-ITD/TKD and NPM1 Fragment Analysis	ITDs in exons 14 and 15 of FLT3, TKD mutations at FLT3 codons encoding D835/I836, and insertions in the last exon of NPM1.	
FLT3-ITD MRD NGS	ITDs in exons 14 and 15 of FLT3	
FIP1L1::PDGFRA qPCR	All common FIP1L1::PDGFRA fusion variants	

*Claimable through Medicare if eligible: Medicare Item Numbers 73447, 73399, 73398, 73314, 73325, 73326

SAMPLE REQUIREMENTS:

• RNA testing: NPM1 MRD, KMT2A-X MRD and FIP1L1-PDGFRA
Blood and BM must be received within 48 hours of collection.
 9ml peripheral blood (EDTA) OR
 2-4ml of bone marrow (EDTA) OR
 WC pellet resuspended in Trizol
 RNA (minimum 10ul at 200ng/µl)

BILL PATIENT DIRECT DECLARATION: Billing of Non-Medicare Rebatable Tests

The pathology request that you have been given by your medical practitioner includes tests that could be either partially or not covered by Medicare.

If required, the full cost of testing must be covered by the patient or, in the case of children, their family. Alfred Pathology requires your consent to proceed with this testing with the full understanding that you will accept responsibility for payment.

Patient Name:

Test Name(s) : _____

The cost of the test requested by your doctor is estimated at A\$

I hereby agree to accept responsibility for full payment or part payment of non-Medicare rebatable tests performed by Alfred Pathology.

Patient/ Parent Signature _____

Date___/__/___

For further information, please contact Alfred Pathology on 9076 3118.